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Background: Vascular Smooth Muscle Cells (VSMCs), due to their plasticity and ability to shift from a physiological
contractile-quiescent phenotype to a pathological proliferating-activated status, play a central role in the onset and
progression of atherosclerosis and cardiovascular diseases. PDGF-BB, among a series of cytokines and growth
factors, has been identified as the critical factor in this phenotypic switch. In order to obtain new insights on the
molecular effects triggered by PDGF-BB, a hammerhead ribozyme targeting the membrane receptor PDGFR-β was
applied to inhibit PDGF pathway in porcine VSMCs.
Findings: Ribozymes, loaded on a cationic polymer-based vehicle, were delivered into cultured VSMCs. A significant
impairment of the activation mechanisms triggered by PDGF-BB was demonstrated since cell migration decreased
after treatments. In order to functionally validate the effects of PDGFR-β partial knock down we focused on the
phosphorylation status of two proteins, protein disulfide isomerase-A3 (PDI-A3) and heat shock protein-60 (HSP-60),
previously identified as indicative of VSMC phenotypic switch after PDGF-BB stimulation. Interestingly, while PDI-A3
phosphorylation was counteracted by the ribozyme administration indicating that PDI-A3 is a factor downstream
the receptor signalling cascade, the HSP-60 phosphorylation status was greatly increased by the ribozyme
administration.
Conclusion: These contradictory observations suggested that PDGF-BB might trigger different parallel pathways
that could be modulated by alternative isoforms of the receptors for the growth factor. In conclusion the knock
down strategy here described enables to discriminate between two tightly intermingled pathways. Moreover it
opens new attractive perspectives in functional investigations where combined gene knock down and proteomic
technologies would allow the identification of key factors and pathways involved in VSMC-linked pathological
disorders.
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Coronary artery disease (CAD) is a pathological status
induced by the reduction or block of the bloody flow
caused by atherosclerotic plaques narrowing or obstruct-
ing the arterial lumen. It is well-known that VSMCs play
a central role in the onset and progression of the disease
and also in the complications observed after Percutaneous* Correspondence: caterina.lande@yahoo.it
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reproduction in any medium, provided the orTransluminal Coronary Angioplasty (PTCA) that repre-
sents the most frequent clinical approach to CAD.
Indeed, VSMCs may change their quiescent-contractile
physiological phenotype, once subjected to external stim-
uli, such as cytokines and growth factors, and acquire
an activated state endowed with proliferative and migra-
tory properties.
Among the activating growth factors, PDGF-BB, pro-
duced by activated platelets and macrophages, has so far
been the only factor demonstrated to selectively and dir-
ectly promote the VSMC phenotype switch [1,2]. The
role of PDGF receptors has been described in post injurytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ies following balloon angioplasty [4]. As a consequence
of their induced activation, VSMCs migrate to the sub-
intimal space, proliferate, and secrete abundant amounts
of extracellular matrix, which forms the bulk of the in-
timal hyperplastic lesion contributing to restenosis [5].
A series of conventional cytostatic drugs has been
adopted to prevent VSMC proliferation and migration
after PTCA but a consistent percentage of side effects
has been described [6]. More selective nucleic acid-
based drugs have been proposed and experimented [7].
Among these drugs, the most frequently exploited ones
are ribozymes and siRNAs. Both these inhibitors are
interesting since they may be tailored to target and
inhibit selectively the genes of interest. The last decade
has been characterized by an extraordinary siRNA
uptrend, due to the low cost and easy availability. Never-
theless, siRNAs display some disadvantages, since they
may saturate cellular machineries and induce off-target
effects [8]. Conversely, ribozymes, although more com-
plicated and time consuming in the design, synthesis
and validation, are self-acting and more specific.
Hammerhead trans-acting ribozymes are the smallest
RNA molecules capable of endonucleolytic activity that
specifically bind and cleave RNA sequences of definite
targets. Impressively, these precise molecular tools are
able to discriminate between targets differing by a single
nucleotide [9] and this is the main reason why they have
been repeatedly proposed as therapeutic agents also in
the field of cardiovascular diseases [10]. In the last years,
a different application of ribozymes has stood out with
the impressive development of proteomics technologies.
This paper describes the design and experimentation
of a hammerhead ribozyme-mediated gene knock down
strategy able to dissect PDGF-BB signaling pathway
in order to evidence how a single receptor can activate
alternative signaling cascades thus emerging as import-
ant switch in VSMC phenotype modulation.
Findings
Methods
Oligonucleotides sequences, synthesis and purification
Selection of target sequence within the porcine PDGFR-
β [sequence accession number AF347050S1] and of
related minimal ribozyme has been performed according
to our previously described predictive method [11].
Selected sequences were: active hammerhead ribozyme,
5′ UCC UUG CUG AUG AGG CCG AAA GGC CGA
AAC CAU AU 3′, inactive hammerhead ribozyme, 5′
UCC UUG CUA AUG AGG CCG AAA GGC CGA
AAC CAU AU 3′ (in bold the inactivating mutation)
and short mRNA substrate, 5′ GUC AUA UGG UUC
AAG GAC AAC 3′, containing the cleavage target trip-
let GUU mimicking the position 288–290 of the mRNA.Syntheses have been performed by phosphoramidite
chemistry in an AB 3400 synthesizer (Applied Biosys-
tems) using a home-adapted coupling protocol. Crude
oligonucleotides were de-protected by treatment with
2 mL of a 1:3 (v/v) mixture of ethanol and 33% ammo-
nium hydroxide (Sigma Aldrich) at 55°C for 12 h and
then concentrated to dryness. Crude products were
desalted by gel-filtration chromatography in a Sephadex
G25 column run in sterile water. Oligonucleotides were
then purified by semi-preparative anion-exchange HPLC
chromatography on 1.6x10 cm SourceW 15Q column
(GE Healthcare) eluted at 6 mL/min with 30 min linear
gradient from 0.25 to 0.75 M NaCl in 20 mM Tris–HCl
buffer pH 9.0 supplemented with 10% acetonitrile (v/v).
A recovered fraction, was desalted, as before, by Sepha-
dex G25 gel-filtration chromatography. The freeze-dried
collected products were treated with 1:3 (v/v) solution of
N,N-dimethylformamide and triethylamine trihydro-
fluoride (Sigma Aldrich) to remove the 2′O tetrabutyldi-
methylsilylic protective group. Free products, desalted
once again by gel-filtration, were UV quantified at
260 nm absorption measurements in a UV–VIS spectro-
photometer (FluoSTAR) before use. A dye-labeled 25mer
DNA oligonucleotide (OligoF) was also synthesized.
In vitro measurement of kinetic constants
A multiple turnover kinetic assay was performed in
standard conditions (37°C, pH 7.4, [Mg+2] = 10 mM)
using a constant 0.2 μM ribozyme concentration and
variable amounts of substrate in order to obtain ratios of
ribozyme to substrate of 1:10, 1:40, 1:120, 1:180. Stock
Ribozyme substrate solutions were separately prepared
in a reaction buffer containing 10 mM MgCl2, and then
heated at 95°C for 2 minutes to denature any secondary
structure of RNA molecules. Cleavage reactions were
started by adding a constant amount of ribozyme to the
substrate solutions at 37°C. At fixed time point (1′, 2′,
3′, 6′, 9′, 12′, 15′, 20′) aliquots were drawn from the re-
action mixture and the reaction stopped by adding
50 mM EDTA to abolish the Mg+2 contribute to ribo-
zyme activity. Recovered fractions were then analyzed by
ion-exchange liquid chromatography using a 4 × 250 mm
DNA-PakW PA-200 column (DIONEX). Runs were per-
formed in a “200 series” apparatus (Perkin Elmer) at 50°
C with a flow rate of 1 mL/min under a 30 min linear
gradient from 100 to 340 mM sodium perchlorate
(Sigma-Aldrich) in 20 mM Tris–HCl buffer pH 9.5 sup-
plemented with 10% acetonitrile. UV signals (recorded at
260 nm) enabled us to quantify the full-length substrate
and cleavage products.
Synthesis of the vehicle A41-PEI
A two-step synthesis was performed according to our pre-
vious experience [12]. Firstly, 6.5 nmol of Polyethylenimine
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were reacted at 37°C for 3 h with 650 nmol of the
bifunctional succinimidyl 4-[N-maleimidomethyl]cyclo-
hexane-1-carboxylate (SMCC) crosslinker dissolved in
DMSO. Unreacted SMCC was removed by 10000 mo-
lecular weight cut-off centrifugation at 10000 rpm for
20 min at 18°C (Microcon YM10, Millipore). The
maleimide-activated PEI was then reacted overnight at
room temperature with 650 nmol of the cystein modified
third helix homeodomain fragment of the Drosophila
Melanogaster antennapedia transcription factor (A41):
CRQIKIWFQNRRMKWKK (Espikem, Italy). Final purifi-
cation was obtained by further 45 min cut-off centrifuga-
tion at 10000 rpm , at 18°C, using the same centrifugal
filter as before in order to discard any unreacted A41.
The purified A41-PEI vehicle was quantified by absorp-
tion measurement at 280 nm (CARY 100, Varian).
VSMC isolation and cultures
Coronaries were dissected from the myocardium of 8-
month-old domestic pigs (Sus scrofa domestica) obtained
from a local slaughterhouse (operating under the local
institutional legislation according to ethical directives).
VSMCs from tunica media were isolated by enzymatic
digestion according to the method described by Christen
et al. [13] and cultured in DMEM HG (GIBCO) medium
containing 10% FBS (Fetalclone). All reported experi-
ments were performed using cells between the second
and sixth passage.
Oligonucleotide transfections into VSMCs
The oligonucleotide delivery to cells was performed
using the described A41-PEI vehicle. The oligonucleotide
amount to be charged onto vehicle, tested under variable
N/P ratio (theoretical amine to phosphate groups ratio),
was optimized by using the fluorescent OligoF. VSMCs
were seeded in 12-well plates at a density of 100,000
cells/well for transfection experiments. After 24 hr, fresh
medium, supplemented with 10% FBS and containing
oligonucleotide-loaded vehicle, corresponding to 250 nM
of ribozyme or OligoF, was added to the wells. 24 hr later,
the cells were, washed in PBS and then either cultured
for biological assays or fixed for immunofluorescence.
Immunofluorescence analysis
Immunofluorescence analyses were carried out on cells
grown and transfected on coverslips. The cells were
fixed at 4°C for 30 min with 2% paraformaldehyde in
PBS and the fluorescence images were recorded using a
DMLB microscope (Leica Microsystems).
Quantitative real-time PCR
Primers designed to produce a 137 bp amplification
product from PDGFR-β mRNA encompassing thecleavage site of hammerhead ribozyme were: forward
primer 5′ GACGCCGTGCAA 3′ and reverse primer 5′
GACAGCGCGATCTC 3′. Similar size product from β-
actin housekeeping reference transcript was designed
and relative primers were: forward 5′CCAACCGCGA-
GAAGATGA 3′ and reverse CCAGAGGCGTACAGG-
GATAG 3′. Crude RNA was extracted from control
(untreated) or 24 hr ribozyme-treated VSMCs using
RNAeasy extraction kit (Qiagen). Aliquots containing
1 μg of total RNA were retrotranscribed using Quanti-
Tect reverse transcription kit (Qiagen) according to
manufacturer’s instructions. Quantitative real-Time PCR
(qRT-PCR) was carried out with LightCycler 480 (Roche
Applied Science). Reactions were performed using Light-
Cycler 480 SYBR Green I Master kit (Roche) under
standard conditions. Relative quantification of mRNA
was calculated with standard curve method. Transcript
values were normalized with those obtained for β-actin
(internal control). Each point represents the mean ± SE
of at least three independent experiments.
Cytotoxicity assay
For the determination of cell viability, VSMCs were
seeded in 96-well culture plates at a density of 1000 cells
in 100 μL of complete medium per well. 24 hr after
seeding, cells were transfected as described above and at
interval of 24 hr after transfection 20 μL of 3-(4.5-
dimethylthiazole-2-yl)-2.5-diphenyl tetrazolium bromide
(MTT) reagent (CellTiter 96W Cell Proliferation Assay,
Promega) were added to each well. Following 2 hr of
incubation at 37°C to allow color development, absorb-
ance was recorded using a 96-well plate reader (Fluostar
Omega, BMG Labtech). Viability tests were carried out
on untreated as well as treated VSMC cultures using
three concentrations (115 nM, 220 nM, 330 nM) of both
active and inactive ribozymes. All measurements were
performed in triplicate.
Wound assay
VSMCs were plated and transfected with 250 nM of ac-
tive or inactive ribozymes in 12-well plates, as described
above. 24 hr after transfection, a straight scratch, simu-
lating a wound, was made on the cell layer using a pip-
ette tip. Thereafter, 10 ng PDGF-BB were added to the
wells for every ml of culture medium. 24 hr later, the
cells were fixed with formalin and stained with crystal
violet. A dedicated image analysis program (Optiquant,
Packard Instruments) allowed the quantification of cells
that had migrated into the scratch.
Chemotaxis assay
Chemotaxis was measured using the CultrexW Cell
Migration Assay (Trevigen Inc.) according to the manufac-
turer’s instructions. Briefly, this assay utilizes a simplified
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ephthalate (PET) membrane. PDGF-BB (10 ng/mL) was
used as chemoattractant. Detection of cell migration was
quantified using Calcein AM (acetomethylester). Calcein
AM is internalized by the cells and intracellular esterases
cleave the AM. Free Calcein fluoresces brightly and the
fluorescence is used to quantitate the number of cells that
have migrated using a standard curve. 50 000 cells were
seeded in each well. Plate was read with a Microplate
Luminometer (Glomax Multi Detection System – Promega)
using a 485 nm excitation and 520 nm emission conditions.
2D-PAGE, mass spectrometry and western blot
Crude proteins were extracted as described by Rocchiccioli
et al [14] from VSMCs, treated or not with oligonucleotide
inhibitors, stimulated for 10 min with PDGF-BB. Protein
content was quantified by standard bicinchoninic acid
(BCA) assay. Proteins were separated by isoelectrofocusing
(IEF) according to the method originally described in Görg
et al. [15] using pre-manufactured strips with an immobi-
lized non-linear pH gradient ranging from 3 to 10 (Amer-
sham Biosciences, Uppsala, Sweden) on a Ettan IPGphor
system (Amersham Biosciences). Second dimension was
run on a 9-16% sodium dodecyl sulfate - polyacrylamide
gel gradient (SDS- PAGE). Gels were stained in ammoni-
acal silver nitrate according to the method described in
Hochstrasser et al. [16]. The analysis of digital images was
carried out with Image Master computer software (Gene-
Bio, Geneva, Switzerland) and only those spots with over
3-fold changes in volume after normalization between the
different samples were defined as altered.
Electrophoretic spots were excised and proteins were
in-gel digested by trypsin. Peptides were analysed by
mass spectrometry (4800 MALDI TOF/TOF - Applied
Biosystems).Identification of the proteins was carried out
using MASCOT search engine version 2.1 (Matrix Sci-
ence, Boston, MA).
For immunodetection of Tyrosine-phosphoproteins,
after separation by 2D-PAGE, proteins were transferred
onto nitrocellulose membranes (Hybond-C, Amersham
Life Science). Membranes were incubated overnight at 4°
C with a mouse anti-phosphotyrosine monoclonal anti-
body (IgG2b; Santa Cruz Biotechnology) diluted 1:1,000
in 3% BSA, 0.1% Tween-20 in PBS and then with the
secondary antibody, HRP-conjugated anti-mouse IgG
(Santa Cruz Biotechnology), diluted 1:3,000, for 1 h at
room temperature. Chemiluminescence was detected by
an ECL™ Detection Kit (Amersham Biosciences) follow-
ing the manufacturer’s protocol.
Statistical analysis
Data were statistically elaborated using the unpaired
t-test (* P< 0.05, ** P< 0.01, ***P< 0.001). Each result
refers to three independent experiments.Results and discussion
Kinetic characterization and transfection
of hammerhead ribozymes
Although some difficulties due to the fact that gene
banks provide only two fragments of the sequence of
porcine PDGFR-β messenger RNA (access numbers
AF347050S1, AF347050S2), we were able to draw a map
of potentially suitable NUH canonical cleavage sites.
A GUU triplet starting at nucleotide 288 of the
AF347050S1 sequence was selected on the basis of its
accessibility indexes (evaluated to be 66.3% for the left
binding element and 78.9% for the right element) and of
the structural features of the corresponding ribozyme
(displaying a calculated −11.3 kcal/mol ΔG° formation
free energy value). Both parameters are suitable to pro-
vide potentially active ribozymes [17]. Specifically opti-
mized chemical synthesis protocols ensured a> 98% of
mean coupling step efficiency and produced a consider-
able amount (85 nmole; 0.9 mg) of purified product.
Ribozyme catalytic activity was monitored by “in vitro”
measurements of cleavage kinetics performed on the
short synthetic target substrate by an HPLC-based
method [18].The direct correlation between the peak
area corresponding to target and those corresponding to
the products allowed the calculation of the reaction rates
and of the kinetic parameters (Figure 1A).
The kcat value of 12.8 min
-1 is indicative of a high rate
of the cleavage step, usually ranging from 1 to 10 min-1
for synthetic minimal hammerhead ribozymes. The cata-
lytic efficiency, i.e. the turnover number kcat/KM, was
0.31 106 min-1 M-1, a value comparable with those
described for other biologically active ribozymes [18,19].
A polymer-based vehicle was designed according to
our previous experience [12]. Polyethyleneimine (PEI
25 k) instead of poly-L-lysine was adopted due to its
lower toxicity and higher activity as transfecting agent
[20]. Moreover, PEI is a commercially available, univer-
sally accepted vehicle and can be considered the golden
standard among the non-viral transfecting agents. As
cell penetrating peptide (CPP) we adopted the third
helix homeodomain fragment (A41) of the Drosophila
Melanogaster antennapedia transcription factor since it
is a characterized by a high efficiency to cross the cell
membranes [21,22]. The number of A41 molecules
bound to primary amino-groups of PEI ranged around a
ratio of 1 to 10 which was previously observed to repre-
sent an optimized compromise between delivery effective-
ness and toxicity. The ultrafiltration-coupled preparation
method of vehicle enabled to obtain a 60% yield from
starting reagents.
Transfection efficiency of vehicle was monitored under
different N/P ratios (amine group of PEI over phosphate
groups of oligonucleotides) exploiting OligoF and evalu-
ating the content of incorporated fluorescence into
Figure 1 Kinetic characterization and ribozyme transfection. A) Graph describing the Eadie-Hofstee interpolation of experimental kobs
values (v0/[Riboz]) calculated for the in vitro cleavage of synthetic substrate under multiple turnover conditions. The resulting kinetic parameters
are also indicated. B) fluorescence microscopy image of VSMCs after OligoF administration. The intracellular fluorescence demonstrates the
oligonucleotide internalization.
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conditions (N/P = 6), 48% of cells became fluorescent
due to the intake of OligoF. A saturation of delivery
activity (over the 90% of cells) was reached for N/P
higher than 17. Such results demonstrate the active
synergistic effect of membrane-fusogenic A41 peptide
which improves the ability of the complex “vehicle/
oligonucleotide” to cross the cell membrane.
The uptake of the oligonucleotide into the cells was
also checked at morphological level by fluorescence light
microscopy analyses. Perinuclear fluorescence was
evident in 90% of the cells and appeared to be clustered
into small roundish vesicles (Figure 1B).
PDGFR-β knock down assessment and toxicity
of the treatments
Relative expression levels of PDGFR-β mRNA as obtained
by qRT-PCR have been normalized to reference value 1
for proliferating VSMCs cultured in standard conditions
(Figure 2A). Active ribozyme treated cultures display a
30% reduction of PDGFR-β messenger RNA if compared
to untreated cells. By contrast, the inactive ribozyme was
totally ineffective. Such results demonstrate that the active
ribozyme is effective and moreover its inhibitory activity
is still present after 24 hr treatment nevertheless the
documented vulnerability of short naked RNA. Unlikely,
it was not possible to assess the decrease in protein
expression due to the unavailability of specific antibodies
raised against the porcine antigenes.
Viability tests after treatments with three different
amount of active or inactive ribozymes have been per-
formed up to 5 days. Cells were cultured in the presence
of the ribozyme bound to the A41-PEI vehicle at con-
stant N/P ratio of 17. Records of the formazan product
by absorbance at 490 nm was measured at 24 h intervals
(Figure 2B). No substantial differences can be observedeither between active and inactive ribozymes also among
the different doses used. The slight delay in the curves,
observed in all oligonucleotide-treated cultures as com-
pared to controls, might reflect the overall cell perturb-
ation provided by the polyplexed complex (vehicle +
oligonucleotide).
Effects of PDGFR-β gene knock down on VSMC migration
Histogram in Figure 3A shows that stimulation of the
cells, obtained by adding PDGF-BB to complete
medium, increased six times the effects of migratory ac-
tivity if compared to quiescent (i.e. cultured in the ab-
sence of serum) VSMCs. The administration of active
ribozyme resulted in a 90% inhibition of PDGF-BB sti-
mulated repair of wound. On the contrary, the inactive
ribozyme produced a considerably reduced effect,
namely a 17% inhibition. This last inhibitory activity
may depend on the antisense effect of inactive ribozyme
as it has been previously suggested [23].
Chemotaxis (Figure 3B) was also analysed in Boyden
chambers using PDGF-BB as chemoactrator. The num-
ber of migrating cells was significantly reduced of about
32% by the ribozyme administration as compared to un-
treated or inactive ribozyme treated cultures.
Knock down-induced changes on protein phosphorylation
This study was triggered by a previous published work
[24] in which PDGF-BB resulted to heavily affect the
phosphoproteome profile of VSMCs. Among other fac-
tors, heat-shock proteins and other chaperones have
been indicated to participate actively to cell remodeling
after growth factor stimulation and to contribute to the
so called “inside-out” cross talk, responsible of the cell
activation [5]. In particular, HSP-60 and PDI-A3 seemed
interesting for the assessment of our partial knock down
system since HSP-60 has been well demonstrated as
Figure 2 PDGFR-β knock-down assessment and toxicity. A) Histogram of Real-time PCR amplification of RNA recovered from VSMCs. Control
bar represents the results obtained with VSMCs cultured in complete medium and normalized to 1 as reference value. Gray bars represent mean
± SE of three independent experiments. Statistical significance was calculated applying the unpaired t-test (* P< 0.05). B) Graph of summarizing
MTT assay. VSMCs were cultured in standard condition for the control or in the presence of active (aHHR) and inactive ribozymes (iHHR). Each
point represents the mean ± SD of 3 independent replicates.
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suggested role in VSMC migration [26,27]. Accumulat-
ing evidence has revealed the presence of chaperones
(HSP-60 and PDI-A3) on cell surface and it has also pro-
posed that their tyrosine phosphorylation might consti-
tute a possible mechanism for reorientation of receptor
complexes and key molecules in the process of cell acti-
vation [28-30]. This mechanism is particular interesting
in the VSMC phenotypic switch that characterizes theirFigure 3 Migration activity of VSMCs cultured under different conditi
VSMCs cultured in absence of serum; PDGF accounts for VSMCs stimulated
ribozyme or +Inactive ribozyme are VSMCs stimulated as before and treate
by PDGF-BB on VSMCs. Bars represent the mean ± SE of at least three inde
VSMCs were statistically elaborated using the unpaired t-test (* P< 0.05, **activation and entails important changes in membrane
morphology and composition. Major outcome of this
phenomenon is the acquisition of a migratory capability.
In this respect, it has been reported that PDI-A3 func-
tions at the cell surface, where it may be involved in
disulfide exchange required for cell mediated adhesion
by integrins [31]. Interestingly, it has also been shown
that PDI-A3 can mediate conformational changes in
both β1 and β3 integrins, which may lead to cell adhesionons. A)- Wound assay istogram: untreated represents quiescent
for migration with serum supplemented with PDGF-BB; PDGF+Active
d with active or inactive ribozymes. B)- Chemotactic activity induced
pendent experiments. Data computing the migration activities of
P< 0.01).
Figure 4 Proteomic approach to phosphorylation study of PDI-A3 and Hsp-60 chaperones. Middle panel shows the 2D-PAGE mapping of
both proteins after silver staining. Inserts illustrate the immunoblotting results of membranes probed with anti-phosphotyrosine antibody. Upper
inserts refer to HSP-60 while lower inserts describe the PDI-A3 staining.
Lande et al. BMC Research Notes 2012, 5:268 Page 7 of 10
http://www.biomedcentral.com/1756-0500/5/268to a particular substrate [32]. Moreover, PDI-A3 might
be committed with PDGF targeting to its receptors [33].
For all this reasons, PDI-A3 and HSP-60 chaperones were
selected in order to validate our knock-down results.
After ribozyme treatment and PDGF-BB stimulus,
VSMCs were collected, the protein content was extracted
and separated by 2D-PAGE. The spots corresponding to
PDI-A3 and HSP-60 were identified by mass spectrom-
etry analysis. Following electro-transfer on nitrocellulose
membranes, tyrosine-phosphoproteins were immunode-
tected by a specific monoclonal antibody. Representative
images of gel and blots are reported in Figure 4.
Histograms in Figure 5, panel A and B, summarize the
results. The comparison of identified spots was obtained
after image de-noising and normalization to the control
samples to which the arbitrary value of 1 was assigned.
PDI-A3 phosphorylation increased 2,7 fold after PDGF-BB activation, while the receptor partial knock down
abolished this induction. Such effect is highly specific
since treatment with inactive ribozyme showed a phos-
phorylation profile quite close (0.9 fold) to that induced
by the growth factor (Figure 5A). Conversely, HSP-60
phosphorylation, is dramatically increased, under partial
knock down condition, more than 5 times over the
PDGF-BB activated sample and 16 fold over the
untreated cells (Figure 5B) while the inactive ribozyme
administration produces a reduced phosphorylation
level. It is interesting to observe that there is an increase
of HSP-60 phosphorylation after the addition of the
inactive ribozyme in comparison to the stimulation with
PDGF. We believe that this outcome is caused by an
already described [23] antisense effect due to the fact
that the inactive ribozyme binds its target but it is not
able to cut the molecules.
Figure 5 Phosphorylated protein comparative analyses. A) Histogram of PDI-A3 phosphorylation . B) Histogram of HSP-60 phosphorylation.
Untreated: refers to quiescent VSMCs. Gray scale value of untreated samples was conventionally assumed to be 1 as normalization factor; PDGF:
refers to VSMCs stimulated with PDGF-BB; PDGF+active ribozyme and PDGF+inactive ribozyme: refer to VSMCs cultured as before and additionally
treated with active or inactive ribozyme. Bars represent the mean ± SE of at least three independent experiments. Data were statistically
elaborated using the unpaired t-test (* P< 0.05, ** P< 0.01, *** P< 0.001).
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With the administration of hammerhead ribozymes, a
significant reduction of the PDGFR-β target mRNA was
obtained. This treatment appeared devoid of any toxic
side effects and considerably affected the PDGF-BB sig-
naling activity as revealed by biological assays. Indeed,Figure 6 Working model describing the different effects on PDI-A3 an
Ribozyme might impair the β-β and α-β dimer formations decreasing the o
abolish) the PDGFR-β signaling pathway and conversely increase the PDGFmigration activity in ribozyme-treated cultures, moni-
tored by wound assay, fell down to 10% of levels attribu-
ted to PDGF stimulated cells. The specificity of such
a knocking down effect was confirmed by the very
small inhibition induced by similar administration of the
inactive ribozyme.d HSP-60 phosphorylation due to PDGFR-β knock-down.
pportunities of PDGF-BB binding. This inhibition might reduce (if not
R-α pathway.
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duced opposite effects on tyrosine phosphorylation of
the chaperones PDI-A3 and HSP-60 although a compar-
able inductive effect triggered by PDGF-BB on both pro-
teins. A possible interpretation of these data is that the
PDGFR-β partial knock down causes an unbalance
among the different PDGF receptors. It is well-known
that PDGF-BB binds both structurally similar protein-
tyrosine kinase receptor subunits (PDGFR-α and
PDGFR-β) and that dimerization and autophosphoryla-
tion of PDGFR occur upon receptor-ligand interaction.
Moreover, differential binding of initial signaling mole-
cules to phosphorylated PDGFRs is thought to mediate
overlapping but distinct α- and β-PDGFRs-induced sig-
naling pathways. In murine fibroblasts, it has been
demonstrated that PDGF-BB activation of β-PDGFR
induces both pro- and anti-transformation pathways,
while activation of PDGFR-α promotes transformation
pathway through phosphorylation/activation of different
signaling molecules [34]. Given that in our experiments
the β isoform was specifically knocked down, after treat-
ment, the α-α homodimer would become the prevalent
competitor for growth factor binding. Consequently, it is
conceivable that PDI-A3 phosphorylation after VSMC
activation could depend on signaling triggered by the
β-containing receptors (sensitivity to knock down) while
HSP-60 phosphorylation could depend on α-containing
receptors whose signaling would be prevalent after β iso-
form removal (Figure 6).
The model described in this figure, once confirmed,
would open new attractive perspectives in studies of
functional proteomics. Combined proteomic and gene
knock down technologies would enable the identification
of key factors and key pathways involved in VSMC acti-
vation and eventually suggest crucial elements suitable
for diagnostic evaluations and useful for planning new
therapeutic strategies.
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